• bitcoinBitcoin(BTC)$63,074.00-1.08%
  • ethereumEthereum(ETH)$1,767.54-1.03%
  • tetherTether(USDT)$1.00-0.01%
  • binancecoinBNB(BNB)$582.84-0.61%
  • usd-coinUSDC(USDC)$1.00-0.01%
  • rippleXRP(XRP)$0.982.05%
  • solanaSolana(SOL)$73.511.65%
  • tronTRON(TRX)$0.3084660.59%
  • Figure HelocFigure Heloc(FIGR_HELOC)$1.01-3.83%
  • HyperliquidHyperliquid(HYPE)$66.78-1.69%
  • zcashZcash(ZEC)$924.93-0.37%
  • moneroMonero(XMR)$498.79-1.21%
  • dogecoinDogecoin(DOGE)$0.0587680.38%
  • leo-tokenLEO Token(LEO)$9.300.23%
  • USDSUSDS(USDS)$1.00-0.01%
  • whitebitWhiteBIT Coin(WBT)$61.04-0.84%
  • chainlinkChainlink(LINK)$9.06-0.49%
  • cardanoCardano(ADA)$0.151652-0.12%
  • stellarStellar(XLM)$0.1388780.97%
  • Ethena USDeEthena USDe(USDE)$1.00-0.04%
  • daiDai(DAI)$1.00-0.03%
  • nearNEAR Protocol(NEAR)$3.252.67%
  • bitcoin-cashBitcoin Cash(BCH)$207.890.40%
  • litecoinLitecoin(LTC)$43.74-1.14%
  • RainRain(RAIN)$0.004701-6.34%
  • CantonCanton(CC)$0.0824523.73%
  • uniswapUniswap(UNI)$5.19-0.83%
  • avalanche-2Avalanche(AVAX)$6.98-1.57%
  • tether-goldTether Gold(XAUT)$3,727.92-3.10%
  • suiSui(SUI)$0.72-0.52%
  • the-open-networkGram (prev. Toncoin)(GRAM)$1.02-4.02%
  • USD1USD1(USD1)$1.000.02%
  • Ripple USDRipple USD(RLUSD)$1.00-0.01%
  • Global DollarGlobal Dollar(USDG)$1.00-0.02%
  • hedera-hashgraphHedera(HBAR)$0.056190-0.17%
  • Ondo US Dollar YieldOndo US Dollar Yield(USDY)$1.150.03%
  • paypal-usdPayPal USD(PYUSD)$1.000.00%
  • BittensorBittensor(TAO)$192.400.77%
  • shiba-inuShiba Inu(SHIB)$0.000004-0.54%
  • crypto-com-chainCronos(CRO)$0.042735-1.49%
  • quant-networkQuant(QNT)$151.89-0.42%
  • MemeCoreMemeCore(M)$0.90-0.63%
  • Circle USYCCircle USYC(USYC)$1.140.01%
  • Spiko Amundi Overnight Swap Fund (EUR)Spiko Amundi Overnight Swap Fund (EUR)(EURSAFO)$1.12-0.42%
  • okbOKB(OKB)$86.641.66%
  • Falcon USDFalcon USD(USDF)$1.000.08%
  • aaveAave(AAVE)$108.58-1.46%
  • pax-goldPAX Gold(PAXG)$3,726.51-3.23%
  • United StablesUnited Stables(U)$1.00-0.07%
  • BlackRock USD Institutional Digital Liquidity FundBlackRock USD Institutional Digital Liquidity Fund(BUIDL)$1.000.00%
TradePoint.io
  • Main
  • AI & Technology
  • Stock Charts
  • Market & News
  • Business
  • Finance Tips
  • Trade Tube
  • Blog
  • Shop
No Result
View All Result
TradePoint.io
No Result
View All Result

Demand for weight-loss drugs fuels Eli Lilly stock surge — market cap hits $1.2 trillion

October 29, 2026
in Business
Reading Time: 3 mins read
A A
Demand for weight-loss drugs fuels Eli Lilly stock surge — market cap hits .2 trillion
ShareShareShareShareShare

Eli Lilly stock hit a record high Thursday thanks to a stronger-than-expected earnings report fueled by sales of weight loss drugs Mounjuaro and Zepbound.

The company’s stock jumped 6% to hit a whopping $1.3 trillion valuation after it raised its full-year earnings forecast.

YOU MAY ALSO LIKE

Nvidia’s Jensen Huang agrees to testify before Senate, Chairman Tim Scott says

Why it feels like the entire internet is breaking right now and what’s really going on

Sales of both Mounjaro and Zepbound beat expections by over 5%, solidifying Eli Lilly’s lead in the booming obesity-drug market.


Sales of both Mounjaro and Zepbound beat expections by over 5%, solidifying Eli Lilly’s lead in the booming obesity-drug market. Getty Images

Over half a million patients are using the injections through Medicare, Lilly said. At a reduced, $50-a-month-price tag for them, investors were worried about potential profit losses, but Lilly’s annual forecasted revenue still went up 1% to $92 billion. 

The report underscored just how big of a lead the company has in the multibillion-dollar GLP-1 market. Lilly competitor Novo Nordisk, which makes WeGovy, is valued at about $171 billion, according to Reuters.

Lilly’s recent acquisitions of psychedelic drugmaker AtaiBeckley and clinical biotech vaccine company Cuervo put dents in the profit outlook, according to Reuters. The company reduced forecasted profit shares by 50 cents.


Historical artifacts from the early history of Col. Eli Lilly on display.
Lilly’s recent acquisitions of psychedelic drugmaker AtaiBeckley and clinical biotech vaccine company Cuervo put dents in the profit outlook, according to Reuters. USA TODAY Network via Reuters Connect

But the annual forecast bump was enough to convince investors the company is on the right track, said Greg Halter, director of research at Carnegie Investment Counsel.

“They’re ​spending money so that they can make money down the road,” said Halter, who owns over 16,000 Eli Lilly shares.

Start your day with all you need to know

Morning Report delivers the latest news, videos, photos and more.

Thanks for signing up!

Investors are closely tracking the company’s new oral weight-loss drug Foundayo to see if it can compete with Novo’s oral Wegovy, which is leading in prescriptions. Oral Wegovy saw users shed about 14% of body weight over 64 weeks, while Foundayo ​patients saw a roughly 11% drop in 72 weeks, according to separate studies. 

Lilly’s pill saw 15% fewer sales than expected last quarter.

But voiced confidence it will do better in the across the Pond – Foundayo was launched in the UK earlier this year and is set for other European countries by the end of the year.

Credit: Source link

ShareTweetSendSharePin

Related Posts

Nvidia’s Jensen Huang agrees to testify before Senate, Chairman Tim Scott says
Business

Nvidia’s Jensen Huang agrees to testify before Senate, Chairman Tim Scott says

November 18, 2026
Why it feels like the entire internet is breaking right now and what’s really going on
Business

Why it feels like the entire internet is breaking right now and what’s really going on

November 18, 2026
What tech CEOs have said about Jensen Huang resigning from Nvidia
Business

What tech CEOs have said about Jensen Huang resigning from Nvidia

November 18, 2026
Ken Griffin sells NYC duplex to Jets owner Woody Johnson for M — months after Mamdani’s pied-à-terre tax stunt
Business

Ken Griffin sells NYC duplex to Jets owner Woody Johnson for $58M — months after Mamdani’s pied-à-terre tax stunt

November 17, 2026
Next Post
Marvell in Talks to Buy Nvidia-Backed Lumentum

Marvell in Talks to Buy Nvidia-Backed Lumentum

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Search

No Result
View All Result
The AI Chip Race with Apple’s Former Chief Chip Architect | Power On with Mark Gurman

The AI Chip Race with Apple’s Former Chief Chip Architect | Power On with Mark Gurman

November 15, 2026
Adam Schiff says Dems would ‘win both’ House and Senate if election was today: Full interview

Adam Schiff says Dems would ‘win both’ House and Senate if election was today: Full interview

November 17, 2026
Could Haley Stevens’ endorsement shake up Michigan Senate race?

Could Haley Stevens’ endorsement shake up Michigan Senate race?

November 12, 2026

About

Learn more

Our Services

Legal

Privacy Policy

Terms of Use

Bloggers

Learn more

Article Links

Contact

Advertise

Ask us anything

©2020- TradePoint.io - All rights reserved!

Tradepoint.io, being just a publishing and technology platform, is not a registered broker-dealer or investment adviser. So we do not provide investment advice. Rather, brokerage services are provided to clients of Tradepoint.io by independent SEC-registered broker-dealers and members of FINRA/SIPC. Every form of investing carries some risk and past performance is not a guarantee of future results. “Tradepoint.io“, “Instant Investing” and “My Trading Tools” are registered trademarks of Apperbuild, LLC.

This website is operated by Apperbuild, LLC. We have no link to any brokerage firm and we do not provide investment advice. Every information and resource we provide is solely for the education of our readers. © 2020 Apperbuild, LLC. All rights reserved.

No Result
View All Result
  • Main
  • AI & Technology
  • Stock Charts
  • Market & News
  • Business
  • Finance Tips
  • Trade Tube
  • Blog
  • Shop

© 2023 - TradePoint.io - All Rights Reserved!